Selegiline improves excessive daytime sleepiness in Parkinson's disease: an open-label observational study

• Published in: Chinese medical journal Vol. 135; no. 14; pp. 1762 - 1764
• Main Authors: Zhang, Jinru, Chen, Juping, Li, Jia, Li, Jian, Miao, Hong, Zhu, Xiangyang, Meng, Meng, Han, Yang, Chen, Jing, Cheng, Xiaoyu, Xiong, Kangping, Jin, Hong, Luo, Weifeng, Mao, Chengjie, Liu, Chunfeng
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins 20.07.2022; Lippincott Williams & Wilkins Ovid Technologies; Wolters Kluwer
• Subjects: Activities of daily living; Clinical trials; Correspondence; Disorders of Excessive Somnolence; Dopamine; Drug dosages; Dyskinesia; Humans; Insomnia; Nocturia; Observational studies; Parkinson Disease - drug therapy; Parkinson's disease; Psychosis; Quality of life; Questionnaires; Restless legs syndrome; Selegiline - therapeutic use; Severity of Illness Index; Sleep
• ISSN: 0366-6999; 2542-5641; 2542-5641
• DOI: 10.1097/CM9.0000000000002308

Changes from baseline to Week 3 and Week 8 in ESS, Parkinson's Disease Sleep Scale (PDSS), and Parkinson's Disease Quality of Life Questionnaire 39 (PDQ-39) assessments were analyzed using mixed-effect models (repeated quantitative data, and abnormal distribution). Selegiline has been shown to improve motor symptoms, but other effects were not investigated. Since EDS in patients with PD does not typically respond to dopaminergic therapy, selegiline may be effective in treating this condition. [...]we assessed EDS and sleep quality by ESS and PDSS, not by polysomnography. [...]since selegiline has achieved good results in improving motor symptoms for PD patients,[3,4] we did not assess the motor symptoms, including Unified Parkinson Disease Rating Scale Part III; therefore, the sleep benefits may have resulted from improved motor symptoms.